These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 18433865)

  • 1. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
    Mughal TI; Cross NC; Padron E; Tiu RV; Savona M; Malcovati L; Tibes R; Komrokji RS; Kiladjian JJ; Garcia-Manero G; Orazi A; Mesa R; Maciejewski JP; Fenaux P; Itzykson R; Mufti G; Solary E; List AF
    Haematologica; 2015 Sep; 100(9):1117-30. PubMed ID: 26341525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
    Merx K; Fabarius A; Erben P; Griesshammer M; Reiter A; Hofmann WK; Hehlmann R; Hochhaus A; Lengfelder E
    Ann Hematol; 2013 Jul; 92(7):907-15. PubMed ID: 23525684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation.
    Szpurka H; Gondek LP; Mohan SR; Hsi ED; Theil KS; Maciejewski JP
    Leukemia; 2009 Mar; 23(3):610-4. PubMed ID: 18818701
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
    Tefferi A; Kantarjian H
    Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
    Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
    Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
    [No Abstract]   [Full Text] [Related]  

  • 7. JAK-2V617F mutation in RARS-t: a target for Imatinib therapy?
    Cannizzo E; Carulli G; Azzarà A; Galimberti S; Zucca A; Petrini M
    Leuk Res; 2008 Oct; 32(10):1636-7. PubMed ID: 18433865
    [No Abstract]   [Full Text] [Related]  

  • 8. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
    Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
    Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imatinib--a new perspective in the treatment of tumors].
    Klener P; Klamová H
    Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?
    Wardrop D; Steensma DP
    Br J Haematol; 2009 Mar; 144(6):809-17. PubMed ID: 19120370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Origin of resistance to Imatinib mesylate: lessons learned from this experience].
    Roche-Lestienne C; Mahon FX; Preudhomme C
    Med Sci (Paris); 2004 Dec; 20(12):1125-30. PubMed ID: 15581468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to imatinib mesylate in chronic myeloid leukaemia.
    Melo JV; Chuah C
    Cancer Lett; 2007 May; 249(2):121-32. PubMed ID: 16949736
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.